SlideShare a Scribd company logo
Qualified Person
and
Mi D i tiMinor Deviations
P. Iamartino – EIPG Italian Delegate
Malta, 18th April 2008
Overview
• EMEA Reflection PaperEMEA Reflection Paper
• EIPG Working Group
• Comments of Interested Parties
• Conclusions• Conclusions
EMEA Reflection Paperp
• It was published on March 2006p
• It deals with minor deviations from the
details described in the MA
• It is recognized that “ from time to time• It is recognized that from time to time
minor deviations from the details set out in
h l dthe MA application do occur”
EMEA Reflection Paperp
• The issue is whether a QP may certify and
l h b hrelease such batches
• No harmonised approach exists in the EU• No harmonised approach exists in the EU
• The proposal deals with the one-off type ofThe proposal deals with the one off type of
deviations
• Recurrent deviations are outside the scope
of the EMEA proposalof the EMEA proposal
EMEA Reflection Paperp
A simple and pragmatic approach is proposedA simple and pragmatic approach is proposed,
based on:
1. responsibility of QP to make decisions
2. principles of quality risk management
3. documentation made available on request
EMEA Reflection Paperp
Application criteria:
• deviation is minor, one-off, unplanned
d i ti t ff ti f t ffi• deviation not affecting safety or efficacy
• API and finished products specs not involvedp p
• to assess the need of an on-going stability test
• QRM to be integrated into the QA system
• all deviations to be reviewed as part of the AQR
EMEA Reflection Paperp
• To minimise the occurrence of deviations it• To minimise the occurrence of deviations, it
is requested to remove unnecessary details
from MA application
• Any deviation which may affect the safety or• Any deviation which may affect the safety or
efficacy or compromises the overall quality
must result in a QP decision not to release the
batch
EMEA Reflection Paperp
• A feedback was requested to all interested
parties
• Amendment to Annex 16 was pointed outAmendment to Annex 16 was pointed out
• In February 2007 a new request of reply, on ay q p y,
structured form, was issued
• A meeting with industry representatives and
associations was planned by September 2007p y p
EIPG Working Groupg p
• QP responsibilities and duties is part of
G i lEIPG strategic plan
• A Working Group was set up in Prague• A Working Group was set up in Prague
(2007 G.A.) to prepare a reply to EMEA
• All delegations were invited to give their
comments and contributionscomments and contributions
• An official EIPG document was submittedAn official EIPG document was submitted
to EMEA on September 2007
EIPG Working Groupg p
Innovative Issues
• promotion of quality risk management
i i lprinciples
• increase of QP discretion power and• increase of QP discretion power and
extension of responsibilities
• benefit in time response and in flexibility
from Regulatory Bodiesfrom Regulatory Bodies
EIPG Working Groupg p
Critical Issues
• a cultural change is required for the
i l t ti f QRM i i limplementation of QRM principles
• reducing level of details in MA seemsreducing level of details in MA seems
difficult to be applied to existing dossiers
• more flexible approach is required for
dealing with recurrent deviationsdealing with recurrent deviations
EIPG Working GroupEIPG Working Group
Key PointsKey Points
• incorporation into EU GMPsp
(Annex 16 and other sections of GMPs)
• QP responsibilities and duties• QP responsibilities and duties
• QP reliance on the quality system
• extension of the principles to IMPs
Comments of Interested Parties
Meeting held in London on 26 Sept 2007 with:
APIC/CEFICAPIC/CEFIC
EFPIA
EGAEGA
EIPG
EQPA
EVM
IFAH-EU
ISPEISPE
PDA
PPTAPPTA
AESGP
Comments of Interested Parties
• Most of Interested Parties presentedMost of Interested Parties presented
detailed comments and suggestions
• EFPIA took the lead of the discussion
• A common position was agreed
A presentation as made to EMEA• A presentation was made to EMEA
Comments of Interested Parties
• Reflection Paper generally welcomedReflection Paper generally welcomed
• Most companies not aware of the
Reflection Paper
• Proposal of EMEA not accepted byProposal of EMEA not accepted by
Authorities in some Member States
St t d i l l f d t il• Strong support on reducing level of details
in MA dossiers
Comments of Interested Parties
QP discretion should be broadened
to include:
t d i tirecurrent deviations
minor changes, pending approval of a filed
variation
OOS deviations for non critical attributes
deviations from IMP dossier
not impacting safety or efficacy
Comments of Interested Parties
• To extend the scope to any minor deviation
(starting and packaging materials specs IPCs)(starting and packaging materials specs, IPCs),
provided that safety and efficacy are met
• To clarify that the QP involved in release of
intermediate stage products may adopt the sameg p y p
principles
T l if th t it i t l t• To clarify that it is not always necessary to
perform a formal risk assessment, but an
i f l l i i t blinformal analysis is acceptable
Comments of Interested Parties
• The Reflection Paper is too limited as itThe Reflection Paper is too limited, as it
does not allow for the full qualification and
t bilit f th QP i b t h laccountability of the QP in batch release
decision
• Interested Parties ready to actively
contrib te to re ision of Anne 16 andcontribute to revision of Annex 16 and
GMPs to harmonise the QP role
Comments of Interested Parties
All comments presented to EMEAAll comments presented to EMEA
Principles of the Reflection Paper accepted
by all Member States
Harmonisation on QP role expectedHarmonisation on QP role expected
Agreement on the Annex 16 revision
Further discussion required before
implementationp
Conclusions
1. EIPG was officially recognised among the1. EIPG was officially recognised among the
European professional bodies
2. Broadening of QP discretion power is the
key issue for the next futurey
3. QP qualification and professional
development is part of EIPG strategic plan

More Related Content

What's hot

Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptRegulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan ppt
sandeep bansal
 
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptxINVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
PrachiSharma575050
 
Product life cycle management
Product life cycle managementProduct life cycle management
Product life cycle management
Vikas Rathee
 
Organization structure of EMA and EDQM active Substance Master File.pptx
Organization structure of EMA and EDQM active Substance Master File.pptxOrganization structure of EMA and EDQM active Substance Master File.pptx
Organization structure of EMA and EDQM active Substance Master File.pptx
BhavikaAPatel
 
Plasma master file
Plasma master filePlasma master file
Plasma master file
Sridhar S
 
NSF International and its role in Dietary supplements & Nutraceutical industr...
NSF International and its role in Dietary supplements & Nutraceutical industr...NSF International and its role in Dietary supplements & Nutraceutical industr...
NSF International and its role in Dietary supplements & Nutraceutical industr...
SyedArshiya4
 
Documentation in Pharmaceutical Industry.pptx
Documentation in Pharmaceutical Industry.pptxDocumentation in Pharmaceutical Industry.pptx
Documentation in Pharmaceutical Industry.pptx
AartiVats5
 
Product lifecycle management
Product lifecycle managementProduct lifecycle management
Product lifecycle management
garimasaini33
 
GMP for Nutraceuticals .pdf
GMP for Nutraceuticals  .pdfGMP for Nutraceuticals  .pdf
GMP for Nutraceuticals .pdf
BhavikaAPatel
 
European_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxEuropean_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptx
NikhilBorade5
 
ANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilGaurav Kr
 
International Medical Device Regulators Forum
International Medical Device Regulators ForumInternational Medical Device Regulators Forum
International Medical Device Regulators Forum
SanthiNori1
 
Quality, Safety and Legislation for herbal products in USA.pptx
Quality, Safety and Legislation for herbal products in USA.pptxQuality, Safety and Legislation for herbal products in USA.pptx
Quality, Safety and Legislation for herbal products in USA.pptx
Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Sciences
 
Registration procedure of drugs in european union
Registration procedure of drugs in european unionRegistration procedure of drugs in european union
Registration procedure of drugs in european unionbdvfgbdhg
 
plasma master file in European countries and requirements in letter of intent...
plasma master file in European countries and requirements in letter of intent...plasma master file in European countries and requirements in letter of intent...
plasma master file in European countries and requirements in letter of intent...
Sanjay batra
 
Doc in pharma
Doc in pharmaDoc in pharma
Doc in pharma
maitreyi zaveri
 
GHTF
GHTFGHTF
GHTF
KDivya11
 
Who prequalification program
Who prequalification programWho prequalification program
Who prequalification program
shweta more
 
Quality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaQuality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in India
S S N D Balakrishna Ch
 
NDA/BLA/PMA and 510(k)
NDA/BLA/PMA and 510(k)NDA/BLA/PMA and 510(k)
NDA/BLA/PMA and 510(k)
Navalika Polishetty
 

What's hot (20)

Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptRegulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan ppt
 
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptxINVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
 
Product life cycle management
Product life cycle managementProduct life cycle management
Product life cycle management
 
Organization structure of EMA and EDQM active Substance Master File.pptx
Organization structure of EMA and EDQM active Substance Master File.pptxOrganization structure of EMA and EDQM active Substance Master File.pptx
Organization structure of EMA and EDQM active Substance Master File.pptx
 
Plasma master file
Plasma master filePlasma master file
Plasma master file
 
NSF International and its role in Dietary supplements & Nutraceutical industr...
NSF International and its role in Dietary supplements & Nutraceutical industr...NSF International and its role in Dietary supplements & Nutraceutical industr...
NSF International and its role in Dietary supplements & Nutraceutical industr...
 
Documentation in Pharmaceutical Industry.pptx
Documentation in Pharmaceutical Industry.pptxDocumentation in Pharmaceutical Industry.pptx
Documentation in Pharmaceutical Industry.pptx
 
Product lifecycle management
Product lifecycle managementProduct lifecycle management
Product lifecycle management
 
GMP for Nutraceuticals .pdf
GMP for Nutraceuticals  .pdfGMP for Nutraceuticals  .pdf
GMP for Nutraceuticals .pdf
 
European_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxEuropean_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptx
 
ANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilANVISA regulatory authority of brazil
ANVISA regulatory authority of brazil
 
International Medical Device Regulators Forum
International Medical Device Regulators ForumInternational Medical Device Regulators Forum
International Medical Device Regulators Forum
 
Quality, Safety and Legislation for herbal products in USA.pptx
Quality, Safety and Legislation for herbal products in USA.pptxQuality, Safety and Legislation for herbal products in USA.pptx
Quality, Safety and Legislation for herbal products in USA.pptx
 
Registration procedure of drugs in european union
Registration procedure of drugs in european unionRegistration procedure of drugs in european union
Registration procedure of drugs in european union
 
plasma master file in European countries and requirements in letter of intent...
plasma master file in European countries and requirements in letter of intent...plasma master file in European countries and requirements in letter of intent...
plasma master file in European countries and requirements in letter of intent...
 
Doc in pharma
Doc in pharmaDoc in pharma
Doc in pharma
 
GHTF
GHTFGHTF
GHTF
 
Who prequalification program
Who prequalification programWho prequalification program
Who prequalification program
 
Quality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaQuality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in India
 
NDA/BLA/PMA and 510(k)
NDA/BLA/PMA and 510(k)NDA/BLA/PMA and 510(k)
NDA/BLA/PMA and 510(k)
 

Similar to The Qualified Person and Minor Deviations

CCXG Forum, March 2021, Simon Fellermeyer
CCXG Forum, March 2021, Simon FellermeyerCCXG Forum, March 2021, Simon Fellermeyer
CCXG Forum, March 2021, Simon Fellermeyer
OECD Environment
 
ISO 14064_2018.pdf
ISO 14064_2018.pdfISO 14064_2018.pdf
ISO 14064_2018.pdf
Mau Tau
 
Timo Ligi and Erik Akse, regulatory impact assessment in Montenegro, Budva 18...
Timo Ligi and Erik Akse, regulatory impact assessment in Montenegro, Budva 18...Timo Ligi and Erik Akse, regulatory impact assessment in Montenegro, Budva 18...
Timo Ligi and Erik Akse, regulatory impact assessment in Montenegro, Budva 18...
Support for Improvement in Governance and Management SIGMA
 
EEP Mekong: 6th Call for Proposals Meeting in Yangon, 1 July 2016
EEP Mekong: 6th Call for Proposals Meeting in Yangon, 1 July 2016EEP Mekong: 6th Call for Proposals Meeting in Yangon, 1 July 2016
EEP Mekong: 6th Call for Proposals Meeting in Yangon, 1 July 2016
EEP Mekong
 
EPA H2020 SC5 Info Day: Involving stakeholders to ask the right questions, H...
 EPA H2020 SC5 Info Day: Involving stakeholders to ask the right questions, H... EPA H2020 SC5 Info Day: Involving stakeholders to ask the right questions, H...
EPA H2020 SC5 Info Day: Involving stakeholders to ask the right questions, H...
Environmental Protection Agency, Ireland
 
Presentation Updating the Manufacturing Principles
Presentation Updating the Manufacturing Principles Presentation Updating the Manufacturing Principles
Presentation Updating the Manufacturing Principles
TGA Australia
 
Webinar on Environmental Footprint Screening study
Webinar on Environmental Footprint Screening studyWebinar on Environmental Footprint Screening study
Webinar on Environmental Footprint Screening study
Marisa Vieira
 
A better understanding of the OECD Test Guidelines Programme and the validati...
A better understanding of the OECD Test Guidelines Programme and the validati...A better understanding of the OECD Test Guidelines Programme and the validati...
A better understanding of the OECD Test Guidelines Programme and the validati...
OECD Environment
 
UNEP E.CLARK - 15° Convegno Europeo
UNEP E.CLARK - 15° Convegno EuropeoUNEP E.CLARK - 15° Convegno Europeo
UNEP E.CLARK - 15° Convegno EuropeoCentro Studi Galileo
 
EEP Mekong: 6th Call for Proposals Meeting in Vientiane, 22 June 2016
EEP Mekong: 6th Call for Proposals Meeting in Vientiane, 22 June 2016EEP Mekong: 6th Call for Proposals Meeting in Vientiane, 22 June 2016
EEP Mekong: 6th Call for Proposals Meeting in Vientiane, 22 June 2016
EEP Mekong
 
Module 2rev
Module 2revModule 2rev
Module 2revcomesa15
 
IEA DSM Task XXIV webinar
IEA DSM Task XXIV webinarIEA DSM Task XXIV webinar
IEA DSM Task XXIV webinar
SEA - Sustainable Energy Advice Ltd
 
Sector Specific EIA Guidelines for Oil and Gas Activities in Myanmar - Initia...
Sector Specific EIA Guidelines for Oil and Gas Activities in Myanmar - Initia...Sector Specific EIA Guidelines for Oil and Gas Activities in Myanmar - Initia...
Sector Specific EIA Guidelines for Oil and Gas Activities in Myanmar - Initia...
Ethical Sector
 
Presentation, Karen Hill, SIGMA, Paris, 4 December 2015_English
Presentation, Karen Hill, SIGMA, Paris, 4 December 2015_EnglishPresentation, Karen Hill, SIGMA, Paris, 4 December 2015_English
Presentation, Karen Hill, SIGMA, Paris, 4 December 2015_English
Support for Improvement in Governance and Management SIGMA
 
Audits of Less Complex Entities Update
Audits of Less Complex Entities UpdateAudits of Less Complex Entities Update
Audits of Less Complex Entities Update
International Federation of Accountants
 
ETIP PV conference: 'Photovoltaics: centre-stage in the power system
ETIP PV conference: 'Photovoltaics: centre-stage in the power systemETIP PV conference: 'Photovoltaics: centre-stage in the power system
ETIP PV conference: 'Photovoltaics: centre-stage in the power system
Cluster TWEED
 
ISPC observations on the CRP pre-proposals & what needs to be done
ISPC observations on the CRP pre-proposals & what needs to be doneISPC observations on the CRP pre-proposals & what needs to be done
ISPC observations on the CRP pre-proposals & what needs to be done
International Institute of Tropical Agriculture
 
AGS Members' Day 2015 - Business Practice Presentation
AGS Members' Day 2015 - Business Practice PresentationAGS Members' Day 2015 - Business Practice Presentation
AGS Members' Day 2015 - Business Practice Presentation
ForumCourt
 
Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...
Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...
Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...
TGA Australia
 
2020 GRESB Real Estate & Infrastructure Results - Nordics
2020 GRESB Real Estate & Infrastructure Results - Nordics2020 GRESB Real Estate & Infrastructure Results - Nordics
2020 GRESB Real Estate & Infrastructure Results - Nordics
GRESB
 

Similar to The Qualified Person and Minor Deviations (20)

CCXG Forum, March 2021, Simon Fellermeyer
CCXG Forum, March 2021, Simon FellermeyerCCXG Forum, March 2021, Simon Fellermeyer
CCXG Forum, March 2021, Simon Fellermeyer
 
ISO 14064_2018.pdf
ISO 14064_2018.pdfISO 14064_2018.pdf
ISO 14064_2018.pdf
 
Timo Ligi and Erik Akse, regulatory impact assessment in Montenegro, Budva 18...
Timo Ligi and Erik Akse, regulatory impact assessment in Montenegro, Budva 18...Timo Ligi and Erik Akse, regulatory impact assessment in Montenegro, Budva 18...
Timo Ligi and Erik Akse, regulatory impact assessment in Montenegro, Budva 18...
 
EEP Mekong: 6th Call for Proposals Meeting in Yangon, 1 July 2016
EEP Mekong: 6th Call for Proposals Meeting in Yangon, 1 July 2016EEP Mekong: 6th Call for Proposals Meeting in Yangon, 1 July 2016
EEP Mekong: 6th Call for Proposals Meeting in Yangon, 1 July 2016
 
EPA H2020 SC5 Info Day: Involving stakeholders to ask the right questions, H...
 EPA H2020 SC5 Info Day: Involving stakeholders to ask the right questions, H... EPA H2020 SC5 Info Day: Involving stakeholders to ask the right questions, H...
EPA H2020 SC5 Info Day: Involving stakeholders to ask the right questions, H...
 
Presentation Updating the Manufacturing Principles
Presentation Updating the Manufacturing Principles Presentation Updating the Manufacturing Principles
Presentation Updating the Manufacturing Principles
 
Webinar on Environmental Footprint Screening study
Webinar on Environmental Footprint Screening studyWebinar on Environmental Footprint Screening study
Webinar on Environmental Footprint Screening study
 
A better understanding of the OECD Test Guidelines Programme and the validati...
A better understanding of the OECD Test Guidelines Programme and the validati...A better understanding of the OECD Test Guidelines Programme and the validati...
A better understanding of the OECD Test Guidelines Programme and the validati...
 
UNEP E.CLARK - 15° Convegno Europeo
UNEP E.CLARK - 15° Convegno EuropeoUNEP E.CLARK - 15° Convegno Europeo
UNEP E.CLARK - 15° Convegno Europeo
 
EEP Mekong: 6th Call for Proposals Meeting in Vientiane, 22 June 2016
EEP Mekong: 6th Call for Proposals Meeting in Vientiane, 22 June 2016EEP Mekong: 6th Call for Proposals Meeting in Vientiane, 22 June 2016
EEP Mekong: 6th Call for Proposals Meeting in Vientiane, 22 June 2016
 
Module 2rev
Module 2revModule 2rev
Module 2rev
 
IEA DSM Task XXIV webinar
IEA DSM Task XXIV webinarIEA DSM Task XXIV webinar
IEA DSM Task XXIV webinar
 
Sector Specific EIA Guidelines for Oil and Gas Activities in Myanmar - Initia...
Sector Specific EIA Guidelines for Oil and Gas Activities in Myanmar - Initia...Sector Specific EIA Guidelines for Oil and Gas Activities in Myanmar - Initia...
Sector Specific EIA Guidelines for Oil and Gas Activities in Myanmar - Initia...
 
Presentation, Karen Hill, SIGMA, Paris, 4 December 2015_English
Presentation, Karen Hill, SIGMA, Paris, 4 December 2015_EnglishPresentation, Karen Hill, SIGMA, Paris, 4 December 2015_English
Presentation, Karen Hill, SIGMA, Paris, 4 December 2015_English
 
Audits of Less Complex Entities Update
Audits of Less Complex Entities UpdateAudits of Less Complex Entities Update
Audits of Less Complex Entities Update
 
ETIP PV conference: 'Photovoltaics: centre-stage in the power system
ETIP PV conference: 'Photovoltaics: centre-stage in the power systemETIP PV conference: 'Photovoltaics: centre-stage in the power system
ETIP PV conference: 'Photovoltaics: centre-stage in the power system
 
ISPC observations on the CRP pre-proposals & what needs to be done
ISPC observations on the CRP pre-proposals & what needs to be doneISPC observations on the CRP pre-proposals & what needs to be done
ISPC observations on the CRP pre-proposals & what needs to be done
 
AGS Members' Day 2015 - Business Practice Presentation
AGS Members' Day 2015 - Business Practice PresentationAGS Members' Day 2015 - Business Practice Presentation
AGS Members' Day 2015 - Business Practice Presentation
 
Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...
Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...
Presentation: TGA manufacturing principles update - Adoption of PIC/S Guide t...
 
2020 GRESB Real Estate & Infrastructure Results - Nordics
2020 GRESB Real Estate & Infrastructure Results - Nordics2020 GRESB Real Estate & Infrastructure Results - Nordics
2020 GRESB Real Estate & Infrastructure Results - Nordics
 

More from European Industrial Pharmacists Group

Update and status of the Falsified Medicines Directive (FMD)
Update and status of the Falsified Medicines Directive (FMD)Update and status of the Falsified Medicines Directive (FMD)
Update and status of the Falsified Medicines Directive (FMD)
European Industrial Pharmacists Group
 
Shortages of medicines originating from manufacturing
Shortages of medicines originating from manufacturingShortages of medicines originating from manufacturing
Shortages of medicines originating from manufacturing
European Industrial Pharmacists Group
 
A paradigm shift in clinical trials
A paradigm shift in clinical trialsA paradigm shift in clinical trials
A paradigm shift in clinical trials
European Industrial Pharmacists Group
 
Introduzione al tema serializzazione e tracciabilità
Introduzione al tema serializzazione e tracciabilitàIntroduzione al tema serializzazione e tracciabilità
Introduzione al tema serializzazione e tracciabilità
European Industrial Pharmacists Group
 
Making the case for personalised medicine
Making the case for personalised medicineMaking the case for personalised medicine
Making the case for personalised medicine
European Industrial Pharmacists Group
 
Precision medicines – delivering to patients
Precision medicines – delivering to patientsPrecision medicines – delivering to patients
Precision medicines – delivering to patients
European Industrial Pharmacists Group
 
Verification of Medicinal Products in Europe: An EIPG Perspective
Verification of Medicinal Products in Europe: An EIPG PerspectiveVerification of Medicinal Products in Europe: An EIPG Perspective
Verification of Medicinal Products in Europe: An EIPG Perspective
European Industrial Pharmacists Group
 
Formulation of Protein Based Drugs
Formulation of Protein Based DrugsFormulation of Protein Based Drugs
Formulation of Protein Based Drugs
European Industrial Pharmacists Group
 
PHAR-IN: Competences for industrial pharmacy practice in biotechnology
PHAR-IN: Competences for industrial pharmacy practice in biotechnologyPHAR-IN: Competences for industrial pharmacy practice in biotechnology
PHAR-IN: Competences for industrial pharmacy practice in biotechnology
European Industrial Pharmacists Group
 
Cancer Research UK Formulation Unit
Cancer Research UK Formulation UnitCancer Research UK Formulation Unit
Cancer Research UK Formulation Unit
European Industrial Pharmacists Group
 
Future supply chains for the pharmaceutical industry – a collaborative approach
Future supply chains for the pharmaceutical industry – a collaborative approachFuture supply chains for the pharmaceutical industry – a collaborative approach
Future supply chains for the pharmaceutical industry – a collaborative approach
European Industrial Pharmacists Group
 
New Medicine Evaluation, Scottish Medicines Consortium
New Medicine Evaluation, Scottish Medicines ConsortiumNew Medicine Evaluation, Scottish Medicines Consortium
New Medicine Evaluation, Scottish Medicines Consortium
European Industrial Pharmacists Group
 
CMAC: A national research centre in continuous manufacturing and crystallisation
CMAC: A national research centre in continuous manufacturing and crystallisationCMAC: A national research centre in continuous manufacturing and crystallisation
CMAC: A national research centre in continuous manufacturing and crystallisation
European Industrial Pharmacists Group
 
A View on Drug Shortages from EIPG
A View on Drug Shortages from EIPGA View on Drug Shortages from EIPG
A View on Drug Shortages from EIPG
European Industrial Pharmacists Group
 
Development of Biopharmaceuticals: Structure and Formulation Considerations
Development of Biopharmaceuticals: Structure and Formulation ConsiderationsDevelopment of Biopharmaceuticals: Structure and Formulation Considerations
Development of Biopharmaceuticals: Structure and Formulation Considerations
European Industrial Pharmacists Group
 
Pharma 2014: Rework, Renaissance or Ragnarök?
Pharma 2014: Rework, Renaissance or Ragnarök?Pharma 2014: Rework, Renaissance or Ragnarök?
Pharma 2014: Rework, Renaissance or Ragnarök?
European Industrial Pharmacists Group
 
Industrial Pharmacist Vision of Clinical Trials
Industrial Pharmacist Vision of Clinical TrialsIndustrial Pharmacist Vision of Clinical Trials
Industrial Pharmacist Vision of Clinical Trials
European Industrial Pharmacists Group
 
Implementation of Annex 13 of the EU GMP Guide
Implementation of Annex 13 of the EU GMP GuideImplementation of Annex 13 of the EU GMP Guide
Implementation of Annex 13 of the EU GMP Guide
European Industrial Pharmacists Group
 
Current Landscape for Safety Reporting in Clinical Trials
Current Landscape for Safety Reporting in Clinical TrialsCurrent Landscape for Safety Reporting in Clinical Trials
Current Landscape for Safety Reporting in Clinical Trials
European Industrial Pharmacists Group
 
Regulatory Control of Clinical Trials
Regulatory Control of Clinical TrialsRegulatory Control of Clinical Trials
Regulatory Control of Clinical Trials
European Industrial Pharmacists Group
 

More from European Industrial Pharmacists Group (20)

Update and status of the Falsified Medicines Directive (FMD)
Update and status of the Falsified Medicines Directive (FMD)Update and status of the Falsified Medicines Directive (FMD)
Update and status of the Falsified Medicines Directive (FMD)
 
Shortages of medicines originating from manufacturing
Shortages of medicines originating from manufacturingShortages of medicines originating from manufacturing
Shortages of medicines originating from manufacturing
 
A paradigm shift in clinical trials
A paradigm shift in clinical trialsA paradigm shift in clinical trials
A paradigm shift in clinical trials
 
Introduzione al tema serializzazione e tracciabilità
Introduzione al tema serializzazione e tracciabilitàIntroduzione al tema serializzazione e tracciabilità
Introduzione al tema serializzazione e tracciabilità
 
Making the case for personalised medicine
Making the case for personalised medicineMaking the case for personalised medicine
Making the case for personalised medicine
 
Precision medicines – delivering to patients
Precision medicines – delivering to patientsPrecision medicines – delivering to patients
Precision medicines – delivering to patients
 
Verification of Medicinal Products in Europe: An EIPG Perspective
Verification of Medicinal Products in Europe: An EIPG PerspectiveVerification of Medicinal Products in Europe: An EIPG Perspective
Verification of Medicinal Products in Europe: An EIPG Perspective
 
Formulation of Protein Based Drugs
Formulation of Protein Based DrugsFormulation of Protein Based Drugs
Formulation of Protein Based Drugs
 
PHAR-IN: Competences for industrial pharmacy practice in biotechnology
PHAR-IN: Competences for industrial pharmacy practice in biotechnologyPHAR-IN: Competences for industrial pharmacy practice in biotechnology
PHAR-IN: Competences for industrial pharmacy practice in biotechnology
 
Cancer Research UK Formulation Unit
Cancer Research UK Formulation UnitCancer Research UK Formulation Unit
Cancer Research UK Formulation Unit
 
Future supply chains for the pharmaceutical industry – a collaborative approach
Future supply chains for the pharmaceutical industry – a collaborative approachFuture supply chains for the pharmaceutical industry – a collaborative approach
Future supply chains for the pharmaceutical industry – a collaborative approach
 
New Medicine Evaluation, Scottish Medicines Consortium
New Medicine Evaluation, Scottish Medicines ConsortiumNew Medicine Evaluation, Scottish Medicines Consortium
New Medicine Evaluation, Scottish Medicines Consortium
 
CMAC: A national research centre in continuous manufacturing and crystallisation
CMAC: A national research centre in continuous manufacturing and crystallisationCMAC: A national research centre in continuous manufacturing and crystallisation
CMAC: A national research centre in continuous manufacturing and crystallisation
 
A View on Drug Shortages from EIPG
A View on Drug Shortages from EIPGA View on Drug Shortages from EIPG
A View on Drug Shortages from EIPG
 
Development of Biopharmaceuticals: Structure and Formulation Considerations
Development of Biopharmaceuticals: Structure and Formulation ConsiderationsDevelopment of Biopharmaceuticals: Structure and Formulation Considerations
Development of Biopharmaceuticals: Structure and Formulation Considerations
 
Pharma 2014: Rework, Renaissance or Ragnarök?
Pharma 2014: Rework, Renaissance or Ragnarök?Pharma 2014: Rework, Renaissance or Ragnarök?
Pharma 2014: Rework, Renaissance or Ragnarök?
 
Industrial Pharmacist Vision of Clinical Trials
Industrial Pharmacist Vision of Clinical TrialsIndustrial Pharmacist Vision of Clinical Trials
Industrial Pharmacist Vision of Clinical Trials
 
Implementation of Annex 13 of the EU GMP Guide
Implementation of Annex 13 of the EU GMP GuideImplementation of Annex 13 of the EU GMP Guide
Implementation of Annex 13 of the EU GMP Guide
 
Current Landscape for Safety Reporting in Clinical Trials
Current Landscape for Safety Reporting in Clinical TrialsCurrent Landscape for Safety Reporting in Clinical Trials
Current Landscape for Safety Reporting in Clinical Trials
 
Regulatory Control of Clinical Trials
Regulatory Control of Clinical TrialsRegulatory Control of Clinical Trials
Regulatory Control of Clinical Trials
 

Recently uploaded

THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 

Recently uploaded (20)

THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 

The Qualified Person and Minor Deviations

  • 1. Qualified Person and Mi D i tiMinor Deviations P. Iamartino – EIPG Italian Delegate Malta, 18th April 2008
  • 2. Overview • EMEA Reflection PaperEMEA Reflection Paper • EIPG Working Group • Comments of Interested Parties • Conclusions• Conclusions
  • 3. EMEA Reflection Paperp • It was published on March 2006p • It deals with minor deviations from the details described in the MA • It is recognized that “ from time to time• It is recognized that from time to time minor deviations from the details set out in h l dthe MA application do occur”
  • 4. EMEA Reflection Paperp • The issue is whether a QP may certify and l h b hrelease such batches • No harmonised approach exists in the EU• No harmonised approach exists in the EU • The proposal deals with the one-off type ofThe proposal deals with the one off type of deviations • Recurrent deviations are outside the scope of the EMEA proposalof the EMEA proposal
  • 5. EMEA Reflection Paperp A simple and pragmatic approach is proposedA simple and pragmatic approach is proposed, based on: 1. responsibility of QP to make decisions 2. principles of quality risk management 3. documentation made available on request
  • 6. EMEA Reflection Paperp Application criteria: • deviation is minor, one-off, unplanned d i ti t ff ti f t ffi• deviation not affecting safety or efficacy • API and finished products specs not involvedp p • to assess the need of an on-going stability test • QRM to be integrated into the QA system • all deviations to be reviewed as part of the AQR
  • 7. EMEA Reflection Paperp • To minimise the occurrence of deviations it• To minimise the occurrence of deviations, it is requested to remove unnecessary details from MA application • Any deviation which may affect the safety or• Any deviation which may affect the safety or efficacy or compromises the overall quality must result in a QP decision not to release the batch
  • 8. EMEA Reflection Paperp • A feedback was requested to all interested parties • Amendment to Annex 16 was pointed outAmendment to Annex 16 was pointed out • In February 2007 a new request of reply, on ay q p y, structured form, was issued • A meeting with industry representatives and associations was planned by September 2007p y p
  • 9. EIPG Working Groupg p • QP responsibilities and duties is part of G i lEIPG strategic plan • A Working Group was set up in Prague• A Working Group was set up in Prague (2007 G.A.) to prepare a reply to EMEA • All delegations were invited to give their comments and contributionscomments and contributions • An official EIPG document was submittedAn official EIPG document was submitted to EMEA on September 2007
  • 10. EIPG Working Groupg p Innovative Issues • promotion of quality risk management i i lprinciples • increase of QP discretion power and• increase of QP discretion power and extension of responsibilities • benefit in time response and in flexibility from Regulatory Bodiesfrom Regulatory Bodies
  • 11. EIPG Working Groupg p Critical Issues • a cultural change is required for the i l t ti f QRM i i limplementation of QRM principles • reducing level of details in MA seemsreducing level of details in MA seems difficult to be applied to existing dossiers • more flexible approach is required for dealing with recurrent deviationsdealing with recurrent deviations
  • 12. EIPG Working GroupEIPG Working Group Key PointsKey Points • incorporation into EU GMPsp (Annex 16 and other sections of GMPs) • QP responsibilities and duties• QP responsibilities and duties • QP reliance on the quality system • extension of the principles to IMPs
  • 13. Comments of Interested Parties Meeting held in London on 26 Sept 2007 with: APIC/CEFICAPIC/CEFIC EFPIA EGAEGA EIPG EQPA EVM IFAH-EU ISPEISPE PDA PPTAPPTA AESGP
  • 14. Comments of Interested Parties • Most of Interested Parties presentedMost of Interested Parties presented detailed comments and suggestions • EFPIA took the lead of the discussion • A common position was agreed A presentation as made to EMEA• A presentation was made to EMEA
  • 15. Comments of Interested Parties • Reflection Paper generally welcomedReflection Paper generally welcomed • Most companies not aware of the Reflection Paper • Proposal of EMEA not accepted byProposal of EMEA not accepted by Authorities in some Member States St t d i l l f d t il• Strong support on reducing level of details in MA dossiers
  • 16. Comments of Interested Parties QP discretion should be broadened to include: t d i tirecurrent deviations minor changes, pending approval of a filed variation OOS deviations for non critical attributes deviations from IMP dossier not impacting safety or efficacy
  • 17. Comments of Interested Parties • To extend the scope to any minor deviation (starting and packaging materials specs IPCs)(starting and packaging materials specs, IPCs), provided that safety and efficacy are met • To clarify that the QP involved in release of intermediate stage products may adopt the sameg p y p principles T l if th t it i t l t• To clarify that it is not always necessary to perform a formal risk assessment, but an i f l l i i t blinformal analysis is acceptable
  • 18. Comments of Interested Parties • The Reflection Paper is too limited as itThe Reflection Paper is too limited, as it does not allow for the full qualification and t bilit f th QP i b t h laccountability of the QP in batch release decision • Interested Parties ready to actively contrib te to re ision of Anne 16 andcontribute to revision of Annex 16 and GMPs to harmonise the QP role
  • 19. Comments of Interested Parties All comments presented to EMEAAll comments presented to EMEA Principles of the Reflection Paper accepted by all Member States Harmonisation on QP role expectedHarmonisation on QP role expected Agreement on the Annex 16 revision Further discussion required before implementationp
  • 20. Conclusions 1. EIPG was officially recognised among the1. EIPG was officially recognised among the European professional bodies 2. Broadening of QP discretion power is the key issue for the next futurey 3. QP qualification and professional development is part of EIPG strategic plan